Ioppolo Anna Maria, Longobardo Luca, D'Isa Salvatore, De Gregorio Paola, Manfredi Mariella, De Cesare Nicoletta Bianca
Department of Clinical and Experimental Medicine, Section of Cardiology, Policlinico San Marco, Corso Europa, Zingonia BG, Messina, Italy.
Department of Clinical and Experimental Medicine - Section of Cardiology, University of Messina, Policlinico G. Martino, Messina, Italy.
J Cardiovasc Echogr. 2019 Oct-Dec;29(4):180-182. doi: 10.4103/jcecho.jcecho_57_19.
We describe a case of an 88-year-old woman with a severe bluntly ematic pericardial effusion. Radiological and laboratory examinations excluded all the most common causes of hemopericardium, and the diagnosis of spontaneous hemopericardium associated with the treatment with rivaroxaban was made. This is the first case report describing a hemopericardium in a patient treated with rivaroxaban who did not take other herbal products or drugs that may significantly increase rivaroxaban blood levels. This report emphasizes the need for the careful use of new oral anticoagulants, and the importance of taking in mind uncommon side effects. Spontaneous hemopericardium should be considered in these patients.
我们描述了一例88岁女性患有严重钝性血性心包积液的病例。影像学和实验室检查排除了血心包的所有常见病因，并诊断为与利伐沙班治疗相关的自发性血心包。这是首例关于未服用其他可能显著提高利伐沙班血药浓度的草药产品或药物的利伐沙班治疗患者发生血心包的病例报告。本报告强调了谨慎使用新型口服抗凝剂的必要性，以及牢记罕见副作用的重要性。对于这些患者应考虑自发性血心包。
